Impax Asset Management Group plc Acquires 57,723 Shares of Illumina, Inc. (NASDAQ:ILMN)

Impax Asset Management Group plc grew its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 923.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,973 shares of the life sciences company's stock after acquiring an additional 57,723 shares during the quarter. Impax Asset Management Group plc's holdings in Illumina were worth $8,343,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of ILMN. UMB Bank n.a. raised its holdings in Illumina by 7.0% in the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company's stock valued at $140,000 after acquiring an additional 88 shares in the last quarter. Integrated Advisors Network LLC lifted its position in Illumina by 2.0% in the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock worth $585,000 after purchasing an additional 90 shares during the period. Texas Permanent School Fund Corp increased its holdings in Illumina by 0.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 32,818 shares of the life sciences company's stock valued at $4,507,000 after buying an additional 114 shares during the period. Institute for Wealth Management LLC. raised its stake in shares of Illumina by 4.6% in the 2nd quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company's stock valued at $285,000 after buying an additional 119 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after acquiring an additional 168 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Trading Down 2.0 %

ILMN stock traded down $3.13 during midday trading on Wednesday, reaching $151.83. The company's stock had a trading volume of 2,813,406 shares, compared to its average volume of 2,007,449. The business's 50-day simple moving average is $136.87 and its 200-day simple moving average is $122.92. The stock has a market cap of $24.19 billion, a PE ratio of -15.56 and a beta of 1.13. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $156.66. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. Illumina's quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.33 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 3.62 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ILMN. HSBC upgraded shares of Illumina from a "hold" rating to a "buy" rating and set a $180.00 price target for the company in a research note on Thursday, October 17th. Argus raised Illumina from a "hold" rating to a "buy" rating and set a $150.00 price target on the stock in a research note on Wednesday, August 28th. Barclays increased their price objective on Illumina from $135.00 to $145.00 and gave the stock an "equal weight" rating in a research note on Tuesday. Stephens reissued an "overweight" rating and set a $170.00 price objective on shares of Illumina in a report on Wednesday, July 10th. Finally, Canaccord Genuity Group upped their target price on shares of Illumina from $130.00 to $145.00 and gave the stock a "hold" rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Illumina presently has an average rating of "Moderate Buy" and a consensus target price of $162.18.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.